Hostname: page-component-7c8c6479df-ph5wq Total loading time: 0 Render date: 2024-03-28T17:47:38.979Z Has data issue: false hasContentIssue false

Hyperglycaemia and myoclonus with clozapine

Published online by Cambridge University Press:  02 January 2018

Justin Sauer
Affiliation:
Maudsley Hospital, London SE5 8AZ
Nicola Funnell
Affiliation:
Maudsley Hospital, London SE5 8AZ
Adrianne Reveley
Affiliation:
Maudsley Hospital, London SE5 8AZ
Rights & Permissions [Opens in a new window]

Abstract

Type
The Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2001. The Royal College of Psychiatrists

Sir: Hyperglycaemia and myoclonus have been reported as uncommon adverse events with clozapine treatment. We report two cases in which they occurred together in close temporal association.

Case 1

A 42-year-old African-Caribbean man with a history of severe, treatment-resistant schizophrenia developed myoclonic jerks while taking clozapine 700 mg/day. Eight weeks later he developed diabetic ketoacidosis with a blood glucose of 44 mmol/l, for which he required intensive care treatment. Clozapine treatment was subsequently stopped. Following recovery he was reinstated on clozapine, has not developed further myoclonus and his glucose tolerance is not impaired.

Case 2

A 58-year-old White British man with a history of clozapine-induced hyper-glycaemia was restarted on clozapine 400 mg/day. After 2 weeks he developed severe myoclonus and deterioration of glycaemic control with random serum glucose as high as 21.5 mmol/l. Clozapine treatment was withdrawn. Within 7 days control of his blood sugar was re-established and myoclonus resolved.

Myoclonus has been reported in 0.2% of 24 000 clozapine treated patients on the UK Clozaril Patient Monitoring Service (CPMS) database. Results from case series suggest the incidence may be as high as 2.0% (Reference Safferman, Lieberman and KaneSafferman et al, 1991) to 2.7% (Reference Sajatovic and MeltzerSajatovic & Meltzer, 1996).

Impaired glucose tolerance with clozapine treatment is also probably more common than the 0.4% quoted by the UK CPMS (Linda Annan, Advisor, CPMS, personal communication). In a case-note study of 82 patients, 36.6% were considered to have developed diabetes (Reference Henderson, Cagliero and GrayHenderson et al, 2000). The true prevalence of these adverse events remains to be established.

The association between hyperglycaemia and movement disorders, including myoclonus, has been well documented (Reference Moores and DireMoores & Dire, 1989). Hyperglycaemia is the commonest metabolic disorder to be associated with clonic activities of the extremities and other focal motor phenomena. Correction of the underlying metabolic disturbance prevents further focal seizures or movement abnormalities (Reference Berkovic, Johns and BladinBerkovic et al, 1982).

Since uncontrolled hyperglycaemia is potentially life threatening, the presence of myoclonus in clozapine treated patients may be of use in alerting clinicians to the presence of impaired glucose tolerance.

References

Berkovic, S., Johns, J. & Bladin, P. (1982) Focal seizures and systemic metabolic disorders. Australian and New Zealand Journal of Medicine, 12, 620623.Google Scholar
Henderson, D., Cagliero, E., Gray, C., et al (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistic study. American Journal of Psychiatry, 157, 975981.Google Scholar
Moores, C. & Dire, D. (1989) Movement disorders as a manifestation of nonketotic hyperglycaemia. Journal of Emergency Medicine, 7, 359364.Google Scholar
Safferman, A., Lieberman, J., Kane, J., et al (1991) Update of the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17, 247261.Google Scholar
Sajatovic, M. & Meltzer, H. (1996) Clozapine-induced myoclonus and generalized seizures. Biological Psychiatry, 39, 367370.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.